These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 25183823)
1. Genetically engineered knock-in and conditional knock-in mouse models of cancer. Rappaport A; Johnson L Cold Spring Harb Protoc; 2014 Sep; 2014(9):897-911. PubMed ID: 25183823 [TBL] [Abstract][Full Text] [Related]
2. Mouse models of cancer. Cheon DJ; Orsulic S Annu Rev Pathol; 2011; 6():95-119. PubMed ID: 20936938 [TBL] [Abstract][Full Text] [Related]
3. Genetically modified mouse models for biomarker discovery and preclinical drug testing. Kucherlapati R Clin Cancer Res; 2012 Feb; 18(3):625-30. PubMed ID: 22298895 [TBL] [Abstract][Full Text] [Related]
4. Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers. Arena S; Isella C; Martini M; de Marco A; Medico E; Bardelli A Cancer Res; 2007 Sep; 67(18):8468-76. PubMed ID: 17875685 [TBL] [Abstract][Full Text] [Related]
5. [Genetically engineered mice: mouse models for cancer research]. Szymańska H Postepy Hig Med Dosw (Online); 2007 Oct; 61():639-45. PubMed ID: 17971765 [TBL] [Abstract][Full Text] [Related]
6. Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis. Kasper S J Cell Biochem; 2005 Feb; 94(2):279-97. PubMed ID: 15565647 [TBL] [Abstract][Full Text] [Related]
7. Probing p53 biological functions through the use of genetically engineered mouse models. Attardi LD; Donehower LA Mutat Res; 2005 Aug; 576(1-2):4-21. PubMed ID: 16038709 [TBL] [Abstract][Full Text] [Related]
8. Preclinical in vitro models from genetically engineered mice for breast and colon cancer (Review). Telang N; Katdare M Oncol Rep; 2011 May; 25(5):1195-201. PubMed ID: 21399881 [TBL] [Abstract][Full Text] [Related]
9. Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Lin SC; Lee KF; Nikitin AY; Hilsenbeck SG; Cardiff RD; Li A; Kang KW; Frank SA; Lee WH; Lee EY Cancer Res; 2004 May; 64(10):3525-32. PubMed ID: 15150107 [TBL] [Abstract][Full Text] [Related]
10. Modeling cancer in mice. Jackson-Grusby L Oncogene; 2002 Aug; 21(35):5504-14. PubMed ID: 12154411 [TBL] [Abstract][Full Text] [Related]
11. Mouse models of human cancer as tools in drug development. Holland EC Cancer Cell; 2004 Sep; 6(3):197-8. PubMed ID: 15380508 [TBL] [Abstract][Full Text] [Related]
12. Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice. Stöhr A; Friedrich FW; Flenner F; Geertz B; Eder A; Schaaf S; Hirt MN; Uebeler J; Schlossarek S; Carrier L; Hansen A; Eschenhagen T J Mol Cell Cardiol; 2013 Oct; 63():189-98. PubMed ID: 23896226 [TBL] [Abstract][Full Text] [Related]
13. [Spatio-temporal control of oncogenesis]. Giovannini M Pathol Biol (Paris); 1998 Feb; 46(2):120-1. PubMed ID: 9769926 [TBL] [Abstract][Full Text] [Related]
15. Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation. Konishi H; Karakas B; Abukhdeir AM; Lauring J; Gustin JP; Garay JP; Konishi Y; Gallmeier E; Bachman KE; Park BH Cancer Res; 2007 Sep; 67(18):8460-7. PubMed ID: 17875684 [TBL] [Abstract][Full Text] [Related]
16. Tetracycline-regulated mouse models of cancer. Yeh ES; Vernon-Grey A; Martin H; Chodosh LA Cold Spring Harb Protoc; 2014 Oct; 2014(10):pdb.top069823. PubMed ID: 25275112 [TBL] [Abstract][Full Text] [Related]
17. Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. Singh M; Johnson L Clin Cancer Res; 2006 Sep; 12(18):5312-28. PubMed ID: 17000664 [TBL] [Abstract][Full Text] [Related]